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three-months. RESULTS: Subject Characteristics: N = 18; 
39 + 10 years (22–59); ﬁve males; 15 schizophrenics; BMI > 30.
Waist circumference—(male > 40in)-Baseline (B): 100%, Acute
(A): 60%*, Maintenance (M): 60%* (female > 35in)-(B):100%,
(A):77%*, (M): 77%*. Weight (lbs)—(B):259, (A):247,
(M):250. Cholesterol—(B):203, (A):185*, (M):186*. Triglyc-
erides—(B):151, (A):113*, (M):144. HDL—(B):41, (A):54*,
(M):47*. Glucose—(B):94, (A):85*, (M):91. Exercise compli-
ance (3 X week)—(B):11%, (A):89%*, (M):33%*. Metabolic
Syndrome—(B):50%, (A):11%*, (M):39%. *P < 0.05 (student 
t or X2). CONCLUSION: SPMI subjects had reductions in 
metabolic syndrome risks and improvement in health status
demonstrated by decrease in waist size, glucose, cholesterol and
triglycerides and an increase HDL. Some beneﬁts were lost when
subjects curtailed exercise compliance in maintenance phase. The
sample size limits our ability to make population inferences, 
yet ﬁndings suggest that a psychoeducation program including
nutrition/exercise modules should be universally available,
encouraged and ongoing to have maximum health beneﬁt and
reduction in overall health costs.
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OBJECTIVES: Numerous side effects are known to be associ-
ated with psychotropic medications. In our previous research we
have shown that side effects associated with asthma therapy
affect patient quality of life and medication adherence. The goal
of this study was to explore psychiatric patient perceptions about
side effects and to assess their interaction with quality of life
(QOL, SF-36 RAND questionnaire) and medication compliance
(Morisky scale). METHODS: A convenience sample of 19 con-
secutive patients with psychiatric disorders has been surveyed
(schizophrenia—8, schizoaffective disorder—4, bipolar disorder
—4, recurrent depressive disorder—3). All patients were using
at least one medication for their therapy. The patients were asked
to recall their use of medicines during the last two weeks. The
survey consisted of a symptom checklist (SC) that consisted of
140 side effects associated with most commonly prescribed med-
ications. The patients were asked to indicate whether they expe-
rienced each symptom listed in the checklist and whether they
felt that each symptom they had was caused by their medica-
tions. The patients were also asked to evaluate intensity of their
physical and emotional suffering due to side effects during the
last two-weeks from zero (no suffering) to ten (the most severe
suffering) and indicate the number of days they suffered from
side effects during the last two-weeks. RESULTS: Two parame-
ters of QOL were negatively associated with side effects with
borderline signiﬁcance: intensity of side effects and social func-
tioning (p = 0.06) and limiting of physical functioning and
number of days of suffering from side effects (p = 0.06). There
was no association between medication adherence and side
effects. Lower medication adherence was associated with lower
emotional functioning (p = 0.04). CONCLUSIONS: We con-
cluded that the side effects associated with psychiatric medica-
tions might affect quality of patient care. Further studies with
larger sample size are needed.
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OBJECTIVE: This research was conducted to determine if
history of substance abuse confers poor prognosis in schizo-
phrenia as measured by onset of illness and treatment outcome.
METHODS: This was a post hoc, pooled analysis of four ran-
domized, double-blind, 24–28 week studies of schizophrenia
treatment. All treatment groups were collapsed for a total of
1627 patients and 142 patients with a history of substance abuse
at any time. Positive and Negative Syndrome (PANSS) scores and
onset of illness were compared between patients who had history
of substance abuse (males, n = 116; females, n = 26) and patients
who did not have history of substance abuse (males, n = 932;
females, n = 533) using analysis of variance. RESULTS: Patients
with a history of substance abuse had an earlier onset of illness
in both male and female patients. History of substance abuse also
had a negative effect on treatment outcomes. Speciﬁcally,
patients with a history of substance abuse had less improvement
in PANSS total and subscores than other patients. The differ-
ences in PANSS total (p < 0.01), PANSS positive (p = 0.02),
PANSS negative (p = 0.03), and PANSS general psychopathol-
ogy (p = 0.02) scores were statistically signiﬁcant for male
patients with history of substance abuse. CONCLUSIONS:
History of substance abuse is an important factor to consider
when treating patients with schizophrenia, as these patients have
an earlier onset of schizophrenia and poor response to treatment
compared to other patients. Further studies are needed to deter-
mine if substance abuse promotes schizophrenia onset; or alter-
natively, certain traits predispose individuals to both substance
abuse and schizophrenia.
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OBJECTIVES: Research on the effects of an intervention on hos-
pital length of stay and discharge are often confounded by socio-
economic factors unrelated to the intervention. The Readiness
for Discharge Questionnaire (RDQ) is a newly developed tool
designed to assess readiness for discharge of inpatients with
schizophrenia, independent of socio-economic factors. This
study examined the psychometric properties of the RDQ.
METHODS: The RDQ consists of six items assessing suicidal-
ity/homicidality, control of aggression/impulsivity, activities of
daily living, medication-taking, delusions/hallucinations interfer-
ing with functioning and global clinical status. A ﬁnal yes/no
question assesses readiness for discharge. Data from a pilot study
(n = 149) and a large randomized double-blind study (n = 382)
were used to examine test-retest reliability, construct validity,
and responsiveness. A third study (32 raters, six cases) provided
data on content validity and inter-rater reliability. RESULTS:
The inter-rater reliability was high for all items of the RDQ (reli-
ability coefﬁcient > 0.9) and moderate/high for the readiness for
discharge status (84% agreement, kappa 0.39, polychoric corre-
